Infectious Diseases and Clinical Microbiology

Doç. Dr. Lütfiye Nilsun Altunal

Doctor and researcher Ümraniye Eğitim ve Araştırma Hastanesi İstanbul
COVID-19HIV InfectionsUrinary Tract InfectionsCross Infection
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • COVID-19 5 publications
    Source: OpenAlex / PubMed MeSHView publications
  • HIV Infections 2 publications
  • Urinary Tract Infections 2 publications
  • Cross Infection 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyInfectious Diseases and Clinical Microbiologysaglik.gov.trFrom source
  • Department name at the sourceEnfeksiyon Hastalıklarısaglik.gov.trFrom source
  • InstitutionÜmraniye Eğitim ve Araştırma Hastanesisaglik.gov.trFrom source
  • Area of workCOVID-19Extracted from 5 publications · Model version —From source
  • Publications43 publicationsOpenAlex, ORCID, Europe PMCFrom source
  • ORCID0000-0003-4794-9283ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://umraniyeah.saglik.gov.tr/TR-1514376/doktorlarimiz.html#lutfiye-nilsun-altunalsaglik.gov.tr

Scientific work

Publications on COVID-19

43 publications

  1. Effectiveness and safety of molnupiravir among patients with mild to moderate COVID-19: a prospective, observational, cohort study

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-44971-x PMID 41991956 Open-access full textSource: OpenAlex

  2. Causes of death in people living with human immunodeficiency virus in Türkiye: a multicentre retrospective study

    European Journal of Clinical Microbiology & Infectious Diseases, 2026

    DOI 10.1007/s10096-025-05350-y PMID 41261274 Source: ORCID

  3. Hepatitis B and C seroprevalence is similar, but hepatitis B seroprotection is lower in patients with diabetic foot infection: A multicenter retrospective study of 4,593 adults

    Clinical Epidemiology and Global Health, 2026

    DOI 10.1016/j.cegh.2026.102516 Open-access full textSource: OpenAlex

  4. Multicentre insights into OPAT: a comprehensive analysis of Türkiye's unstructured system

    BMC infectious diseases, 2026

    DOI 10.1186/s12879-026-14269-4 PMID 42754855 1 citation (Europe PMC) Open-access full textSource: Europe PMC

  5. Development of Candidaemia Score ( CanDi ‐Score) in Decision of Early Empirical Antifungal Treatment for Patients in Intensive Care Unit: The International Prospective Observational ID ‐ IRI Study

    Mycoses, 2026

    DOI 10.1111/myc.70213 PMID 42626934 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  6. Impact of the COVID-19 Pandemic on CLABSI Rates and Antibiotic Resistance: A Multicenter Study in Türkiye

    Infectious diseases & clinical microbiology, 2025

    DOI 10.36519/idcm.2025.513 PMID 41111492 Open-access full textSource: Europe PMC

  7. A National Multicenter Study on Initial Antiviral Treatment Preferences on Chronic Hepatitis B: Entecavir Versus Tenofovir Disoproxil Fumarate

    The Turkish Journal of Gastroenterology, 2025

    DOI 10.5152/tjg.2025.24741 PMID 41669932 Open-access full textSource: OpenAlex

  8. Managing Candida auris fungemias: the results of a prospective and international study

    Antimicrobial Agents and Chemotherapy, 2025

    DOI 10.1128/aac.00358-25 PMID 40560092 21 citations (OpenAlex) Open-access full textSource: OpenAlex

  9. Evaluation of Exposure to HAV and Vaccination Status of Chronic HBV Cases - A Nationwide Multicenter Study

    Viral Hepatitis Journal, 2025

    DOI 10.4274/vhd.galenos.2025.2025-2-4 Open-access full textSource: OpenAlex

  10. WED-418 A national multicenter study on initial antiviral treatment preferences on chronic hepatitis B: Entecavir versus Tenofovir disoproxil fumarate

    Journal of Hepatology, 2024

    DOI 10.1016/s0168-8278(24)02226-8 Open-access full textSource: OpenAlex

View all 43 publications